Zantac 150

Quick links to important sections

Zantac 150

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zantac 150

Property Description
Active ingredient Ranitidine Hydrochloride
Form Oral Tablet (also Syrup, Injection)
Pharmacological class Histamine H2 receptor antagonist (H2-blocker)
General purpose Inhibition of gastric acid secretion
Origin Synthetic compound

What Type of Medicine is Zantac 150 and What is its Composition?

Zantac 150 is a pharmaceutical preparation that contains the synthetic compound Ranitidine Hydrochloride as its single active ingredient and is classified as an Histamine H2 receptor antagonist, commonly known as an H2-blocker. The drug possesses a specific binding affinity to the target receptors. The name signifies that the preparation typically delivers 150 mg of Ranitidine per dose, most often in the form of an oral tablet. This single active ingredient product is also available in other dosage forms, including a syrup and a formulation for injection, facilitating the drug's delivery via the oral or intravenous route of administration.


How Does Ranitidine Hydrochloride Generally Achieve its Purpose?

The medication acts as a Gastric Acid Secretion Inhibitor by targeting specific receptors on the stomach lining cells. Ranitidine employs a mechanism of targeted blockade, attaching to the H2 receptors on the parietal cells and preventing the natural signal, Histamine, from triggering acid release. This action results in a significant reduction of hydrogen ion concentration in the stomach. This reduction of gastric acid output is an established characteristic of the drug's pharmacological profile. The medicine works by effectively limiting the stomach's ability to produce excessive acid, a process often utilized in managing general heartburn episodes.


How Does the H2-Antagonist Class Differ from Other Acid Reducers?

The H2-blocker class distinguishes itself by actively preventing the formation of new acid, offering a prolonged reduction in stomach acidity rather than merely treating existing acid. Unlike Antacids, which provide immediate but temporary relief by neutralizing acid already present, H2-antagonists interfere with the chemical process of secretion itself. This mechanism allows the medicine to control acid production over time. They are also differentiated from Proton Pump Inhibitors (PPIs), which block the final pump mechanism in acid production, by acting earlier in the secretion pathway to inhibit both basal and nighttime acid production.

Regulatory References

  1. NIH Ranitidine Reference
  2. European Medicines Agency (EMA)
  3. EMA H2-Antagonist Characterization

What side effects are possible with Zantac 150?

Possible Side Effects and Safety Information

The safety profile for Ranitidine (the active ingredient in Zantac 150) is officially classified by frequency and grouped into specific System-Organ Classes (SOCs), as documented in government regulatory labeling. This categorization establishes the full spectrum of possible effects across various body systems.

Common adverse reactions, defined as occurring in 1% to 10% of patients, generally involve the Gastrointestinal System (such as constipation or diarrhea) and the Nervous System (including headache or dizziness).

Rare and Very Rare adverse reactions are explicitly listed due to their clinical significance. These include serious effects on the Immune System, such as anaphylactic reactions and angioedema, and effects on the Hepatobiliary System, including hepatitis (with or without jaundice). Rare but serious Hematologic Changes (e.g., agranulocytosis) are also documented.

Population-Specific Safety Notes

The official labeling notes specific safety considerations for certain populations. Older Adults and patients with Renal or Hepatic Impairment have an increased regulatory risk noted for Central Nervous System (CNS) effects, such as confusion or hallucinations. Furthermore, certain adverse reactions, including effects on the Reproductive System (gynaecomastia, impotence), are primarily noted in association with long-term use of the medication.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official overdose profile for Ranitidine Hydrochloride, as documented by government regulatory sources, establishes required emergency actions and describes specific clinical manifestations. Overdose exposures have been reported to result in Central Nervous System (CNS) effects, including reversible mental confusion, agitation, and hallucinations, which are noted to occur predominantly in severely ill elderly patients.

Cardiovascular effects, such as hypotension (low blood pressure) and abnormal heartbeat (tachycardia or bradycardia), are also documented overdose presentations. Severe, life-threatening outcomes, including asystole (cardiac standstill) and hepatic failure, have been associated with high exposures in regulatory records.


Mandated Emergency Action

Official labeling uniformly instructs individuals to seek immediate medical attention or contact a Poison Control Center right away in the event of a suspected or known overdose. Immediate emergency medical attention is also required if severe symptoms like chest pain that spreads to the jaw or shoulder are accompanied by anxiety or light-headedness.


Management Context

Regulators state that no specific antidote is known for Ranitidine overdose. Consequently, the mandated treatment approach in a clinical setting is limited to symptomatic and supportive therapy, which may include monitoring vital signs and using supportive procedures, such as haemodialysis, to remove the drug from the plasma where appropriate.

Therapeutic Uses of Zantac 150

Main Uses and Applications

Zantac 150 is a medication used to manage conditions related to excessive stomach acid. Its primary function is to reduce the production of acid in the stomach lining, which helps alleviate symptoms and promote healing in the upper digestive tract.

Treatment of Heartburn and Acid Indigestion

The most common use for Zantac 150 is the relief of heartburn, often described as a burning sensation in the chest or throat. It is used to manage:

  • Acid indigestion: Discomfort caused by an overabundance of stomach acid.
  • Sour stomach: A condition resulting from acid refluxing into the esophagus.
  • Prevention of symptoms: Taking the medication before consuming food or beverages known to trigger acid production can help prevent the onset of discomfort.

Management of Gastroesophageal Reflux Disease (GERD)

Zantac 150 is utilized in the management of GERD, a chronic condition where stomach acid frequently flows back into the esophagus. By lowering acid levels, the medication helps reduce the irritation of the esophageal lining and supports the healing of erosive esophagitis, which is the physical damage or inflammation caused by long-term acid exposure.

Treatment and Prevention of Ulcers

This medication is also indicated for the treatment and maintenance of various types of ulcers within the digestive system. These include:

  • Duodenal ulcers: Ulcers located in the upper part of the small intestine.
  • Gastric ulcers: Ulcers located within the stomach.

Beyond treating active ulcers, it is often used as maintenance therapy to reduce the risk of ulcer recurrence after the initial healing process is complete.

Hypersecretory Conditions

Zantac 150 is used to treat rare pathological conditions where the stomach produces abnormally high amounts of acid, such as Zollinger-Ellison syndrome. In these cases, consistent acid reduction is necessary to manage systemic digestive issues.

Benefits of Treatment

The primary benefit of Zantac 150 is the restoration of comfort and the protection of the digestive tract. By controlling acid production, the medication provides:

  • Symptom relief: Reduces the frequency and severity of burning sensations and acid-related pain.
  • Tissue healing: Creates an environment that allows damaged esophageal or gastric tissues to repair themselves.
  • Prophylactic support: Offers a preventive measure for individuals who experience predictable acid-related distress due to dietary or lifestyle factors.

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Eligibility and Contraindications: Official Regulatory Information

The most significant regulatory status for ranitidine (Zantac 150) is the market withdrawal requested by the U.S. Food and Drug Administration (FDA) and the recommended suspension in the European Union (EMA) as of April 2020. This action was taken because the medicine was found to contain the impurity N-nitrosodimethylamine (NDMA), a probable human carcinogen, at levels that increase over time and when exposed to higher temperatures.


Classification Population or Condition
Contraindicated Patients with known hypersensitivity (allergy) to ranitidine or any ingredient.
Use Prohibited All consumers and patients, as regulatory agencies requested the immediate withdrawal of all ranitidine products from the market (FDA).
Restricted Use Individuals with kidney disease or impaired renal function (requires doctor consultation for dose adjustment).
Requires Consultation Children under 12 years; pregnant or breast-feeding individuals.
Must NOT Use Patients experiencing signs of a serious condition, such as bloody stools, vomiting with blood, or trouble swallowing.

Before the market withdrawal, Zantac 150 was generally considered eligible for use by adults and children 12 years and over. However, official labeling mandates that use in groups like those with impaired kidney function requires special consideration and dose adjustment. Ultimately, the current global regulatory position, based on a product quality and safety constraint, prohibits the general use and availability of the medicine.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Zantac 150 (ranitidine) can interact with several medicinal products by altering their absorption, metabolism, or elimination. The drug's primary mechanism for interactions involves its effect on gastric pH, which can significantly change the absorption of certain co-administered drugs.

Documented Interaction Categories

Category Mechanism and Implication
pH-Dependent Drugs Reduced gastric acidity may lead to decreased absorption and reduced plasma levels of drugs like ketoconazole, itraconazole, and the antiretroviral atazanavir.
Elimination Competition Ranitidine competes with certain drugs for renal tubular secretion, which can increase the plasma concentration of medicines such as procainamide.
Anticoagulants Co-administration with coumarin anticoagulants (e.g., warfarin) requires close monitoring of prothrombin time due to the documented potential for altered effect.
Select Antivirals Use with atazanavir is not recommended due to a significant reduction in atazanavir plasma levels. Co-administration with delavirdine requires specific timing, administering ranitidine at least two hours apart.

Clinical Considerations

Official regulatory documents classify the interaction with atazanavir as one to avoid due to the critical reduction in the antiviral’s effectiveness. Other combinations, such as with procainamide and warfarin, necessitate close monitoring and potential dosage adjustments by a healthcare professional. These interactions are fundamentally tied to ranitidine's impact on pH and its role in drug elimination pathways. Antacids may also be affected, potentially decreasing ranitidine's absorption when taken simultaneously.

Mechanism of Action

Blocking the Histamine Signal on Parietal Cells

The medication's active compound is classified as a competitive antagonist, which binds to and blocks the histamine H2-receptors on the stomach's acid-producing cells (parietal cells). This binding interrupts the chemical signal transmitted by histamine, which normally stimulates acid release.

Modulating Gastric Acid Secretion

Interruption of the upstream histamine signal modulates the intracellular cascade that precedes the activation of the final acid-secreting structure. This mechanistic step results in a reduction in the volume and concentration of hydrogen ions (acidity) released into the stomach lumen, which modifies the chemical conditions of the upper gastrointestinal tract.

Dosage and Administration Information

The administration of ranitidine (Zantac 150) is governed by specific guidelines detailing the route, schedule, and duration of use. The medication is approved for oral intake, which includes tablets, effervescent tablets, and syrup, as well as parenteral administration via intravenous or intramuscular injection.

The core usage pattern involves a standardized dosing schedule. For acute treatment, the standard dose is 150 mg taken twice daily, or 300 mg taken once daily at bedtime. This regimen defines the frequency and magnitude of the dose. Long-term use for maintenance therapy is typically 150 mg once daily at bedtime, often following a short-term acute course lasting between 4 and 8 weeks.

Administration instructions clarify the need for dose adjustment in specific patient populations. For patients with renal impairment (Creatinine Clearance < 50 mL/min), the oral dose is reduced to 150 mg every 24 hours to prevent accumulation. Furthermore, it is noted that the tablet dose is not required to be timed with meals, though OTC use for prevention should be 30 to 60 minutes before symptom-causing food. Pediatric use is guided by a weight-based formula, with a maximum daily dose of 300 mg. This structured approach ensures the medicine is administered according to a standardized plan, whether for a short acute course or a prolonged maintenance period.

Recent Clinical Evidence

Ranitidine, the active compound in Zantac 150, is a histamine H2-receptor antagonist historically used for conditions involving excessive stomach acid production. Clinical trials established its efficacy for treating and maintaining healing of duodenal and gastric ulcers, as well as managing symptoms of Gastroesophageal Reflux Disease (GERD) and erosive esophagitis. The 150 mg dosage was commonly utilized for maintenance therapy following the healing of acute ulcers and for the short-term symptomatic relief of heartburn.

Efficacy Profile

Clinical research has demonstrated that ranitidine works by reversibly binding to the H2 receptors on gastric parietal cells, resulting in a reduction of gastric acid secretion. Studies comparing ranitidine to placebo in the management of duodenal ulcers showed significantly higher healing rates. For maintenance of healed duodenal ulcers, long-term studies indicated that a substantial majority of patients remained ulcer-free for multiple years while receiving treatment.

Safety and Regulatory Status

While previous long-term data suggested a favorable safety profile, regulatory concerns arose regarding the potential formation of N-nitrosodimethylamine (NDMA), a probable human carcinogen, in ranitidine products. These concerns were based on laboratory tests suggesting that NDMA levels in some products could increase over time, especially when stored at higher temperatures. As a result, many global health agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), requested the withdrawal of all ranitidine products from the market in 2020. However, some newer formulations of ranitidine have been subsequently approved by the FDA following extensive safety reviews aimed at preventing the formation of NDMA.

Frequently Asked Questions (FAQ)

Common questions about Zantac 150 (FAQ)

Q: What is the main reason Zantac 150 is prescribed?

Ranitidine is approved by regulatory agencies to treat conditions caused by excess stomach acid. These conditions include stomach and intestinal ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and hypersecretory conditions such as Zollinger-Ellison syndrome.

Q: Is Zantac 150 different from the version that was taken off the market?

The ranitidine products previously withdrawn were found to contain the impurity NDMA. Regulatory agencies have since approved a reformulated version that has undergone extensive safety testing specifically designed to address the risk of impurity formation over time and in storage.

Q: Can Zantac 150 be taken for general stomach discomfort?

Ranitidine is officially indicated for the treatment of specific conditions related to excess stomach acid, such as heartburn, acid indigestion, and sour stomach. It is not generally labeled for use with unspecified or non-acid-related stomach discomfort.

Q: How quickly does Zantac 150 usually start working after taking a dose?

Official pharmacological data indicates that the onset of action is described as beginning within 55 to 65 minutes after taking a 150 mg dose. This information helps describe the expected time frame for the reduction of stomach acid.

Q: Is it okay to take Zantac 150 every day for a long time?

Official dosing documents define the short-term acute treatment period as up to 8 weeks and maintenance therapy as lasting up to 1 year for prescription use. For the nonprescription version, use is generally restricted to a maximum of 14 consecutive days.

Q: Are there any common foods or drinks that should be avoided while taking Zantac 150?

Regulatory guidance describes limiting or avoiding alcohol consumption and certain foods that may cause an increase in gastrointestinal irritation. General health guidance often advises similar measures while using this medication.

Q: Can I take Zantac 150 if I have a history of kidney problems?

The drug label advises that ranitidine requires dose adjustment for patients with kidney impairment (renal impairment). Therefore, individuals who have kidney problems are advised to consult a health professional regarding the appropriate dosage before use.

Q: What are the most commonly reported side effects people mention with Zantac 150?

According to official product documents, the most frequently reported adverse events in clinical trials include headache, constipation, and diarrhea. This information is intended to provide a general overview of commonly reported effects.

Q: Is Zantac 150 the same type of medicine as proton pump inhibitors (PPIs)?

Ranitidine belongs to a class of drugs known as H2 receptor antagonists, or H2 blockers. This class has a different mechanism of action than proton pump inhibitors (PPIs), which work by blocking the final acid pump in the stomach.

Q: Why does my official information mention certain side effects that seem serious?

Regulatory agencies require drug labels to list all reported adverse events, including both common and rare serious side effects. This is mandated by regulatory agencies to ensure all effects, such as allergic reactions, blood count changes, and mental confusion, are noted in post-market surveillance.

Q: Has there been recent research about the long-term safety of Zantac 150?

Due to regulatory concerns regarding the NDMA impurity in the older version, the U.S. FDA has approved a reformulated ranitidine product. This product has undergone extensive safety testing specifically designed to address the risk of impurity formation during storage and over time.

Q: Do older adults typically experience different effects from Zantac 150 compared to younger adults?

Older adults may be more susceptible to certain Central Nervous System side effects, particularly confusion. Additionally, due to age-related changes in kidney function, the drug's half-life may be prolonged, which may require monitoring.

Q: Can Zantac 150 cause dizziness or problems with driving?

Official adverse event reports have included side effects such as dizziness and somnolence (drowsiness) in rare instances. Potential impairment to operate machinery or drive is noted in connection with these effects.

Q: What should I do if I feel worse after starting Zantac 150?

Regulatory warnings advise that if symptoms of heartburn continue or if the condition worsens during nonprescription use, the medication should be discontinued. Consultation with a health professional is advised for further guidance.

Q: Is Zantac 150 sometimes used for conditions other than heartburn or ulcers?

Ranitidine is officially approved for a range of acid-related conditions beyond simple heartburn and ulcers. These include severe gastroesophageal reflux disease (GERD), erosive esophagitis, and the chronic hypersecretory condition known as Zollinger-Ellison syndrome.

Q: How long does the effect of Zantac 150 typically last?

The pharmacological elimination half-life is typically around 2.5 to 3.0 hours in individuals with normal kidney function. This measure relates to how quickly the substance is removed from the body, and its acid reduction effects are described as lasting several hours.

Q: Does taking Zantac 150 affect the absorption of vitamins or minerals?

Because ranitidine works by reducing the overall amount of stomach acid, it may change how the body absorbs certain other products or medications. This is because some products require an acidic stomach environment to be properly absorbed into the body.

Q: Can Zantac 150 cause skin rash or itching?

Official documents list rash as a reported adverse event. Additionally, rash and itching are noted as signs of a possible serious hypersensitivity reaction, which is a symptom for which seeking medical attention is required by the product label.

Q: Is it safe to take Zantac 150 at the same time as antacids?

Clinical study data indicates that the administration of a potent antacid has been shown to decrease the overall absorption of ranitidine. This information suggests that separating the timing of these two medications is generally appropriate.

Q: Why is Zantac 150 sometimes taken at bedtime?

Ranitidine is frequently administered at bedtime because its acid-lowering effect is described in pharmacological documents as being more pronounced on the body's basal and nocturnal acid secretion. This timing assists in maintenance therapy for certain conditions.

Q: What are the official restrictions on who should not use Zantac 150?

Official restrictions on use include a history of allergy or hypersensitivity to ranitidine or other H2 blockers. Additionally, the drug label advises that use is conditional upon consultation if serious symptoms or pre-existing conditions, such as kidney disease, are present.

Q: Are there specific symptoms that mean I should stop taking Zantac 150 immediately?

The product label details that discontinuation of use and immediate medical attention are necessary if signs of a serious condition occur. these include trouble breathing, severe signs of an allergic reaction, bloody vomit, or bloody/black stools.

Q: Is Zantac 150 a controlled substance?

Ranitidine is not classified as a controlled substance under the Controlled Substances Act (CSA) schedule in the United States. It is a non-scheduled medication.

Q: What is the typical age range for people who are prescribed Zantac 150?

Ranitidine is approved for use in both adults and children. Prescription dosing regimens are available for infants as young as 1 month old, based on a weight-based formula, and for older children and adults.

Q: Do lifestyle changes need to be made while taking Zantac 150?

Regulatory patient information mentions that non-drug measures, such as dietary changes, stress reduction, and limiting alcohol consumption, may complement the treatment effects of the medication. These measures are often part of managing acid-related conditions.

Q: Is it normal to feel a change in bowel habits when taking Zantac 150?

Changes in bowel habits are reported adverse events associated with the use of ranitidine. Specifically, both constipation and diarrhea have been noted in official product documents.

Q: Does Zantac 150 have any known drug-drug interactions that are considered major?

Ranitidine can interact with certain prescription drugs by reducing stomach acid, which may affect how the body absorbs them. Official documents list specific interactions with certain antivirals and azole antifungals.

Q: How is the safety of Zantac 150 monitored by regulatory agencies?

Regulatory agencies continually monitor the safety of medications through official post-market surveillance programs. These programs rely on healthcare professionals and encourage consumers to report any suspected adverse reactions.

Q: What information is available regarding Zantac 150 use during pregnancy?

Ranitidine is categorized by the FDA as Pregnancy Category B, meaning animal studies have not demonstrated a risk to the fetus. Official guidance describes that use during pregnancy is conditional and is considered only when deemed clearly needed by a health professional.

Q: Can Zantac 150 affect liver function?

There have been occasional reports of ranitidine use being associated with changes in liver function, including hepatitis (liver inflammation). These effects are generally described as reversible upon discontinuation of the medication.

Q: What is the risk of allergic reaction with Zantac 150?

Rare cases of serious hypersensitivity reactions, including anaphylaxis (severe, life-threatening allergic reaction) and angioedema (swelling beneath the skin), have been reported in official documents.

Q: Is Zantac 150 effective for all types of acid reflux?

Ranitidine is officially indicated for the treatment of conditions related to excess stomach acid, including certain forms of gastroesophageal reflux disease (GERD) and erosive esophagitis. Its approved use defines the scope of its reported effectiveness.

Q: Are there reports of Zantac 150 causing mental or mood changes?

Rare instances of Central Nervous System effects, such as mental confusion, dizziness, depression, and hallucinations, have been noted in official reports. These reports primarily involve severely ill or elderly patients.

Q: Does Zantac 150 affect blood pressure?

Official adverse event reports have rarely included cardiovascular events such as arrhythmias (irregular heart rhythms). The label does not indicate a common effect on blood pressure.

Q: Is Zantac 150 available over-the-counter or only by prescription?

Ranitidine has been available in both prescription and nonprescription (over-the-counter) formulations. The nonprescription products are generally used for the short-term relief of heartburn.

Q: Are there different brand names for the same active ingredient in Zantac 150?

The active ingredient in Zantac 150 is ranitidine. As is common with many medications, this active ingredient may also be marketed under various generic names or other brand names internationally.

Q: What if I take Zantac 150 and it doesn't seem to help my symptoms?

The product label advises that nonprescription use should be discontinued if symptoms do not improve. Consultation with a health professional is advised if symptoms do not improve.

Q: Are there restrictions on taking Zantac 150 if I have a history of blood disorders?

Official warnings advise patients to inform a health professional if they have a history of a certain blood disorder, specifically porphyria. Official documents also report rare cases of adverse events involving changes in blood cell counts.

Q: Does the effectiveness of Zantac 150 decrease over time?

The class of medication to which ranitidine belongs (H2 blockers) is noted in clinical literature for the potential to gradually lose effectiveness with continuous long-term use. This effect is sometimes referred to as tachyphylaxis.

Q: Can Zantac 150 be taken with or without food?

For prescribed use, ranitidine tablets can be taken either with or without food, as noted in the product information. However, when taking the nonprescription (over-the-counter) version for the prevention of heartburn, official guidance indicates it should be taken 30 to 60 minutes before consuming food or beverages that cause symptoms.

How should Zantac 150 be stored and disposed of?

Storage and Disposal of Ranitidine (Zantac 150)

Official Storage Requirements

Official labeling mandates that ranitidine tablets be stored at 20° to 25°C (68° to 77°F), which aligns with USP Controlled Room Temperature. The product must be stored in a tight, light-resistant container and be actively protected from light and excessive heat or humidity. It is also a mandatory requirement that this medicine be kept out of the reach of children.

Official Disposal Instructions

Following the regulatory request for market withdrawal, the U.S. Food and Drug Administration (FDA) advises consumers to stop taking any ranitidine product they possess and dispose of it properly at home. The product is not on the FDA's flush list. Safe disposal involves mixing the medicine (without crushing tablets) with an unappealing substance, placing the mixture in a sealed bag, and discarding it in the household trash. Empty containers should have personal information removed before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zantac 150 found in:

A-Z Index: